The Acute Effects of Different Spironolactone Doses on Oxidative Stress in Streptozotocin-Induced Diabetic Rats

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–787. ZimmetP AlbertiKG ShawJ Global and societal implications of the diabetes epidemic Nature 2001 414 782 787 Search in Google Scholar

2. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 2015;6(13):1246–1258. LeonBM MaddoxTM Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research World J Diabetes 2015 6 13 1246 1258 Search in Google Scholar

3. Mayyas F, Alzoubi KH, Bonyan R. The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes. Cardiovasc Ther 2017;35(2):e12242. MayyasF AlzoubiKH BonyanR The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes Cardiovasc Ther 2017 35 2 e12242 Search in Google Scholar

4. Silva MAB, Bruder-Nascimento T, Cau SBA, Lopes RAM, Mestriner FLAC, Fais RS, et al. Spironolcatone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol 2015;6:269. SilvaMAB Bruder-NascimentoT CauSBA LopesRAM MestrinerFLAC FaisRS Spironolcatone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling Front Physiol 2015 6 269 Search in Google Scholar

5. Silva MA, Cau SB, Lopes RA, Manzato CP, Neves KB, Bruder-Nascimento T, et al. Mineralocorticoid receptor blockade prevents vascular remodeling in a rodent model of type 2 diabetes mellitus. Clin Sci (Lond.) 2015;129(7):533–545. SilvaMA CauSB LopesRA ManzatoCP NevesKB Bruder-NascimentoT Mineralocorticoid receptor blockade prevents vascular remodeling in a rodent model of type 2 diabetes mellitus Clin Sci (Lond.) 2015 129 7 533 545 Search in Google Scholar

6. Delcayre C. and Silvestre JS. Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999;43(1):7–12. DelcayreC SilvestreJS Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999 43 1 7 12 Search in Google Scholar

7. Patel BM, Kakadiya J, Goyal RK, Mehta AA. Effect of Spironolactone on Cardiovascular Complications Associated with Type-2 Diabetes in Rats. Exp Clin Endocrinol Diabetes 2013;121:441–447. PatelBM KakadiyaJ GoyalRK MehtaAA Effect of Spironolactone on Cardiovascular Complications Associated with Type-2 Diabetes in Rats Exp Clin Endocrinol Diabetes 2013 121 441 447 Search in Google Scholar

8. Garg R, Rao AD, Baimas-George M, Hurwitz S, Foster C, Shah RV, et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015;64(1):236–42. GargR RaoAD Baimas-GeorgeM HurwitzS FosterC ShahRV Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes Diabetes 2015 64 1 236 42 Search in Google Scholar

9. Vranic A, Simovic S, Ristic P, Nikolic T, Stojic I, Srejovic I, et al.. The acute effects of different spironolactone doses on cardiac function in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 2017;95(11):1343–1350. VranicA SimovicS RisticP NikolicT StojicI SrejovicI The acute effects of different spironolactone doses on cardiac function in streptozotocin-induced diabetic rats Can J Physiol Pharmacol 2017 95 11 1343 1350 Search in Google Scholar

10. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the reninangiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007;148:3773–3780. StasS Whaley-ConnellA HabibiJ AppeshL HaydenMR KaruparthiPR Mineralocorticoid receptor blockade attenuates chronic overexpression of the reninangiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling Endocrinology 2007 148 3773 3780 Search in Google Scholar

11. Toda N, Nakanishi S, Tanabe S. Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol 2013;168:519–533. TodaN NakanishiS TanabeS Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications Br J Pharmacol 2013 168 519 533 Search in Google Scholar

12. Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, Price DA, Laffel LM, et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 2004;65:1435–1439. HollenbergNK StevanovicR AgarwalA LansangMC PriceDA LaffelLM Plasma aldosterone concentration in the patient with diabetes mellitus Kidney Int 2004 65 1435 1439 Search in Google Scholar

13. Tveden-Nyborg P, Bergmann TK, Lykkesfeldt J. Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. Basic Clin Pharmacol Toxicol 2018;123(3):233–235. Tveden-NyborgP BergmannTK LykkesfeldtJ Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies Basic Clin Pharmacol Toxicol 2018 123 3 233 235 Search in Google Scholar

14. Pick E, Keisari Y. A simple colometric method for the measurement of hydrogen peroxide by cells in culture. J Immunol Methods 1980;38:161–170. PickE KeisariY A simple colometric method for the measurement of hydrogen peroxide by cells in culture J Immunol Methods 1980 38 161 170 Search in Google Scholar

15. Green LC, Wagner DA, Glogowski J, Skipper PI, Wishnok JS, Tannenbaum SR Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. Anal Biochem 1982;126:131–138. GreenLC WagnerDA GlogowskiJ SkipperPI WishnokJS TannenbaumSR Analysis of nitrate, nitrite and (15N) nitrate in biological fluids Anal Biochem 1982 126 131 138 Search in Google Scholar

16. Auclair C, Voisin E. Nitroblue Tetrazolium reduction. In: Greenwald RA (ed) Handbook of methods for oxygen radical research. CRP Press, Boca Raton, 1985. pp 123–132. AuclairC VoisinE Nitroblue Tetrazolium reduction In: GreenwaldRA (ed) Handbook of methods for oxygen radical research CRP Press Boca Raton 1985 123 132 Search in Google Scholar

17. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–358. OhkawaH OhishiN YagiK Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal Biochem 1979 95 351 358 Search in Google Scholar

18. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment Clinical Science 2004;107:539–557. HayatSA PatelB KhattarRS MalikRA Diabetic cardiomyopathy: mechanisms, diagnosis and treatment Clinical Science 2004 107 539 557 Search in Google Scholar

19. Li YW, Aeno WS. Diabetes Mellitus and Cardiovascular Disease. J Clinic Experiment Cardiol 2011;2:114. LiYW AenoWS Diabetes Mellitus and Cardiovascular Disease J Clinic Experiment Cardiol 2011 2 114 Search in Google Scholar

20. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595–602. RublerS DlugashJ YuceogluYZ KumralT BranwoodAW GrishmanA New type of cardiomyopathy associated with diabetic glomerulosclerosis Am J Cardiol 1972 30 595 602 Search in Google Scholar

21. Van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive - diabetic heart disease. Circulation 1990;82:848–85. Van HoevenKH FactorSM A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive - diabetic heart disease Circulation 1990 82 848 85 Search in Google Scholar

22. Poornima IG, Parkih P, Shanon RP. Diabetic Cardiomyopathy: search for unifying hypoyhesis Circ Res 2006;98:596–605. PoornimaIG ParkihP ShanonRP Diabetic Cardiomyopathy: search for unifying hypoyhesis Circ Res 2006 98 596 605 Search in Google Scholar

23. Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, et al. Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy. Curr Cardiol Rev 2010;6:280–290. WatanabeK ThandavarayanRA HarimaM SariFR GurusamyN VeeraveeduPT Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy Curr Cardiol Rev 2010 6 280 290 Search in Google Scholar

24. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Molecular Endocrinol 2006;20:953–970. HunyadyL CattKJ Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II Molecular Endocrinol 2006 20 953 970 Search in Google Scholar

25. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A. et al. Myocardial cell death in human diabetes. Circ Res 2000;87:1123–1132. FrustaciA KajsturaJ ChimentiC JakoniukI LeriA MaseriA Myocardial cell death in human diabetes Circ Res 2000 87 1123 1132 Search in Google Scholar

26. Robert V, Heymes C, Silvestre JS. Angiotensin AT1receptor subtype as a cardiac target of aldosterone: role in aldosterone salt induced fibrosis. Hypertension 1999;33:981–986. RobertV HeymesC SilvestreJS Angiotensin AT1receptor subtype as a cardiac target of aldosterone: role in aldosterone salt induced fibrosis Hypertension 1999 33 981 986 Search in Google Scholar

27. Nagatomo Y, Meguro T, Ito H, Koide K, Anzai T, Fukuda K. et al. Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy. PLoS One 2014;9(3):e93145. NagatomoY MeguroT ItoH KoideK AnzaiT FukudaK Significance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy PLoS One 2014 9 3 e93145 Search in Google Scholar

28. Verma S, Violet GY, Badiwala M, Anderson JT, McNiel LH. Working heart function in diabetes is not improved by spironolactone treatment Can J Physiol Pharmacol 2003;81:493–496. VermaS VioletGY BadiwalaM AndersonJT McNielLH Working heart function in diabetes is not improved by spironolactone treatment Can J Physiol Pharmacol 2003 81 493 496 Search in Google Scholar

29. Ojeda-Cervantes M, Barrera-Chimal J, Alberú J, Pérez-Villalva R, Morales-Buenrostro LE, Bobadilla NA. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study. Am J Nephrol 2013;37(5):481–90. Ojeda-CervantesM Barrera-ChimalJ AlberúJ Pérez-VillalvaR Morales-BuenrostroLE BobadillaNA Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study Am J Nephrol 2013 37 5 481 90 Search in Google Scholar

30. Silva MA, Bruder-Nascimento T, Cau SB, Lopes RA, Mestriner FL, Fais RS, Touyz, RM, Tostes RC. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol 2015;6:269. SilvaMA Bruder-NascimentoT CauSB LopesRA MestrinerFL FaisRS TouyzRM TostesRC Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling Front Physiol 2015 6 269 Search in Google Scholar

31. Kosugi T, Heining M, Nakayama T, Matsuo S, Nakagawa T. eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists. Am J Path 2010;176(2):619–629. KosugiT HeiningM NakayamaT MatsuoS NakagawaT eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists Am J Path 2010 176 2 619 629 Search in Google Scholar

32. Hayashi T, Shibata H, Kurihara I, Yokota K, Mitsuishi Y, Ohashi, K, et al. High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling. Int Heart J 2017;58:794–802. HayashiT ShibataH KuriharaI YokotaK MitsuishiY OhashiK High Glucose Stimulates Mineralocorticoid Receptor Transcriptional Activity Through the Protein Kinase C β Signaling Int Heart J 2017 58 794 802 Search in Google Scholar

33. Barbato JC, Mulrow PJ, Shapiro JI and Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 2002;40(2):130–135. BarbatoJC MulrowPJ ShapiroJI Franco-SaenzR Rapid effects of aldosterone and spironolactone in the isolated working rat heart Hypertension 2002 40 2 130 135 Search in Google Scholar

34. Haas MJ, Jurado-Flores M, Hammoud R, Feng V, Gonzales K, Onstead-Haas L, Mooradian AD. The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion from Human Coronary Artery Endothelial Cells. Am J Therapeut 2019;26(3):e321–e332. HaasMJ Jurado-FloresM HammoudR FengV GonzalesK Onstead-HaasL MooradianAD The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion from Human Coronary Artery Endothelial Cells Am J Therapeut 2019 26 3 e321 e332 Search in Google Scholar

35. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008;14:1370–1376. ShibataS NagaseM YoshidaS KawarazakiW KuriharaH TanakaH MiyoshiJ Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease Nat Med 2008 14 1370 1376 Search in Google Scholar

36. Kawakami-Moori F and Shimosawa T. Oxidative Stress and Mineralocorticoid Receptor Signaling in the Brain: Possible Therapeutic Targets for Dementia. Ann Clin Exp Hypertesion 2012;2(2):1015–1020. Kawakami-MooriF ShimosawaT Oxidative Stress and Mineralocorticoid Receptor Signaling in the Brain: Possible Therapeutic Targets for Dementia Ann Clin Exp Hypertesion 2012 2 2 1015 1020 Search in Google Scholar